Dr. Lal Pathlabs Ltd. share price target

Dr Lal PathLabs’ (Dr Lal) Q1FY25 result was in line with our expectations. Growth was driven by better uptick in Swasthfit (up 26.4% YoY) overall sample volume rose 9.3% YoY.

We met DLPL’s MD Dr. Om Manchanda to gauge competitive intensity and its strategy to boost volumes. Meeting KTAs are: 1) DLPL is increasingly witnessing the ‘bundling’ phenomenon as doctors are recommending multiple tests to ascertain accurate prognosis.

DLPL posted a robust quarter, with revenue growing 11% YoY on the back of
sample volume increasing 9% YoY and Swasthfit contributing 24% to the
topline.

Dr Lal’s Pathlabs’ Q1 volume growth at 2.5% was impacted to some extent due to seasonality. Favourable test mix and traction in Swasthfit improved realisation per patient by 8.5% to INR 789 and aided gross margin expansion of 181bps YoY.

Dr Lal Pathlabs’ (Dr Lal) Q2FY23 performance was a mixed bag with slower-than-
expected growth in non-covid patient volumes, but healthy improvement in margins.

Dr. Lal PathLabs Limited (DLPL) provides diagnostic and related healthcare tests and services in India and internationally. Company has 231 clinical laboratories, including National Reference Lab at Delhi and Regional...

With persistent focus of service parameters and timely turnarounds, DLPL was able to achieve robust growth in volume during the pandemic. Leveraging its dedicated network driven infrastructure and techenabled processes, we expect the company to be able to perform well in the expected third wave situation. Hence, we upgrade our rating on the...

unsustainable rise in volume of patients and samples (all time high) We reinitiate coverage on DLPL stock with Sell' rating, previously kept Under Review'. 1QFY22 earnings were higher than our estimates solely driven by additional volumes, due to large number of patients in the second wave. Business in core portfolio grew 15% YoY given 1) all collection centers and labs resumed operations much earlier than expected 2) high revenue...

Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. Company has 231 clinical laboratories, including National Reference Lab at Delhi and Regional...

Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. Company has 216 clinical laboratories, including National Reference Lab at Delhi and Regional...

The company's growth in COVID business, strong brand recall, gradual unlock of cities should support growth in upcoming quarters. Given the limited upside potential we downgrade our rating to HOLD with a revised target price of Rs. 1,995 based on 53x FY22E EPS. COVID-19 tests contribute to the top line DLPL's Q1FY21 top line went down 20.6% YoY to Rs. 266cr severely impacted by COVID-19 and subsequent lock down impacting the revenue in April (-61% YoY) and May (-12% YoY), however some respite was seen in June (+14% YoY) when cities were...

We remain negative on the entire diagnostic chain with a belief of 1) premium players losing their market share to unorganized players, 2) B2B (40% of revenue) partners negotiating to partially offset their loss of profit, 3) Inability to hike prices causing lower realization level (Revenue/Patient) and 4) higher fixed costs (60-65% of operating cost for DLPL), new compliance expense and home collection of samples will lead to lower EBITDA margin. However even after increased estimate, we maintain SELL' recommendation but revised TP to Rs1,006 (from Rs895) on PE 40x of FY22E due to challenging...

28-30% of revenue compared to last year in Q1FY21E and gradual recovery from Q2FY21E. As per the management, 60-65% of DLPL's total operating cost is fixed in nature and the new additional expense (cost of safety for...

DLPL's strong business model led to a revenue growth of 16.2% CAGR over FY15-19, supported by rise in sample collection (~18.6% CAGR; backed by large network of PSCs 1,600 and PUPs) along with growing number of patient served (+15.5% CAGR). Company's 1,200 Hub and Spoke model (centralized diagnostic testing) offers economies of scale and 800...

Dr Lal PathLabs (DLPL) Q1FY20 earnings came marginally higher than our estimates on account of improved revenue contribution from regions constituting

DLPL's revenue, adj. EBITDA and PAT grew 15%, 21% and 19% YoY Change in Estimates | Target | Reco With strong cash flow and growth in new customers and packaged offer, the...